←Back to Expert Scholars
Translational Medicine / 转化医学Colorectal Cancer, HER2 and Rare Subsets
Kanwal Raghav
MD
🏢MD Anderson Cancer Center🌐USA
Associate Professor, Gastrointestinal Medical Oncology
50
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Kanwal Raghav co-led DESTINY-CRC trials of trastuzumab deruxtecan in HER2 expressing colorectal cancer and has developed treatment strategies for appendiceal and other rare gastrointestinal cancers. His work has expanded antibody drug conjugate options for CRC.
Share:
🧪Research Fields 研究领域
HER2 CRC
DESTINY-CRC
trastuzumab deruxtecan
appendiceal cancer
rare GI tumors
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Kanwal Raghav 的研究动态
Follow Kanwal Raghav's research updates
留下邮箱，当我们发布与 Kanwal Raghav（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment